Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has released its inaugural Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) practices with data primarily from 2020 and highlights from 2021. The report details Amneal's focus on five key impact areas: people, products, governance, planet, and community, including its role in combating COVID-19. The company emphasizes its ongoing dedication to enhancing employee diversity, R&D for affordable medications, and supporting social advocacy.
- Release of inaugural Corporate Responsibility Report highlighting commitment to ESG.
- Focus on enhancing employee diversity and Board capabilities.
- Dedication to affordable access to complex next-generation medicines.
- Emphasis on innovative Specialty products for therapeutic needs.
- Efforts to minimize natural resource consumption in operations.
- None.
Reinforcing its commitment to purpose-driven strategy, performance, and culture
“Since our founding in 2002, we have maintained a deep commitment to the core principles of ESG, and they are integrated throughout our Amneal 2.0 strategy. As we look out over the long-term, we believe all aspects of our company, particularly our people and products, have a profound opportunity to provide a meaningful and lasting impact for our stakeholders and the world,” said Chirag and
By deepening its commitment to ESG practices, Amneal is focused on what matters most: responsibly helping make healthy possible through access to high-quality, accessible medications. The Company is driving that vision in the following ways:
- Strengthening the talent, diversity and capabilities of its employee family and Board of Directors;
- Directing its considerable R&D capabilities to provide affordable access for patients to complex and next generation medicines;
- Deepening its portfolio of innovative Specialty products focused on Central Nervous System/Movement Disorders and Endocrinology to help address unmet therapeutic needs;
- Driving efficiencies across its global facilities and supply chain that minimize consumption of natural resources; and
- Enhancing support for social advocacy, therapeutic communities, employee volunteerism and philanthropic partnerships.
Amneal plans to continue updating key stakeholders on its corporate social responsibility commitments and looks forward to evolving it’s reporting to incorporate guidance from leading ESG standard-setting and framework organizations within future updates.
To view Amneal’s sustainability report, please visit: https://www.amneal.com/about/responsibility/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005262/en/
ESG
Director, ESG Programs and Reporting
Emily.Parlapiano@amneal.com
Investor
Senior Director, Investor Relations
anthony.dimeo@amneal.com
Source:
FAQ
What is the significance of Amneal Pharmaceuticals' Corporate Responsibility Report?
What areas does Amneal Pharmaceuticals' ESG report focus on?
How does Amneal plan to improve its ESG practices going forward?
When was Amneal Pharmaceuticals' Corporate Responsibility Report released?